Elena I Deryugina

US Patent:

20020025510, Feb 28, 2002

Filed:

Jul 26, 2001

Appl. No.:

09/916658

Inventors:

Alex Strongin - San Diego CA, US
Elena Deryugina - San Diego CA, US

International Classification:

C12Q001/00
C12Q001/68
C12N009/64

US Classification:

435/004000, 435/006000, 435/226000

Abstract:

The present invention is directed to a method of identifying an inhibitor or enhancer of activity by contacting superactivated integrin with one or more molecules; and assaying an integrin activity, where reduced activity identifies an inhibitor of activity and where enhanced activity identifies an enhancer of activity. In a preferred embodiment, a cell, such as a MCF-breast carcinoma cell, is transfected with a nucleic acid molecule encoding a superactivated variant, which can have, for example, substantially the amino acid sequence of SEQ ID NO:6 shown in FIG.

US Patent:

20220389113, Dec 8, 2022

Filed:

Nov 6, 2020

Appl. No.:

17/774796

Inventors:

- Acton, Australian Capital Territory, AU
- La Jolla CA, US
- St. Lucia, Queensland, AU
Yaowu HE - Woolloongabba, Queensland, AU
Brittney HARRINGTON - Woolloongabba, Queensland, AU
James QUIGLEY - La Jolla CA, US
Elena DERYUGINA - La Jolla CA, US

International Classification:

C07K 16/28
G01N 33/574
A61K 47/68
A61K 51/10
A61P 35/00
A61P 1/18
C07K 16/30

Abstract:

The present disclosure relates to anti-CDCP1 antibodies, and antigen binding fragments thereof that specifically bind to the full length and cleaved forms CUB domain-containing protein 1 (CDCP1), and conjugates comprising anti-CDCP1 antibodies and uses thereof for treatment and detection of cancer.